SAGE Therapeutics (SAGE) Receives a Hold from Morgan Stanley
In a report released today, Matthew Harrison from Morgan Stanley maintained a Hold rating on SAGE Therapeutics (SAGE), with a price target of $81.00. The company’s shares closed last Monday at $76.37.
According to TipRanks.com, Harrison is a 5-star analyst with an average return of 16.8% and a 58.6% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Freeline Therapeutics Holdings, and BioMarin Pharmaceutical.
Currently, the analyst consensus on SAGE Therapeutics is a Moderate Buy with an average price target of $98.31, which is a 31.9% upside from current levels. In a report issued on April 12, Mizuho Securities also maintained a Hold rating on the stock with a $81.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $98.39 and a one-year low of $30.33. Currently, SAGE Therapeutics has an average volume of 478.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.
Read More on SAGE: